Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study

Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study

Ripretinib, a novel tyrosine kinase inhibitor used in advanced gastrointestinal stromal tumors (GIST) resistant to standard therapies, was assessed in the United Kingdom (UK) within an Expanded Access Program (EAP). A retrospective review of patients treated between January 2020 and October 2021 wit...

Full description

Bibliographic Details
Main Authors: Su Yin Lim, Laura Ferro-López, Elizabeth Barquin, Daniel Lindsay, Khin Thway, Myles J. Smith, Charlotte Benson, Robin L. Jones, Andrea Napolitano
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Cancers
Subjects:
gastrointestinal stromal tumor
GIST
ripretinib
expanded access
real-world data
Online Access:https://www.mdpi.com/2072-6694/16/5/985

Internet

https://www.mdpi.com/2072-6694/16/5/985

Similar Items